Bahrain's Vaccine Strategy: Choice And Rollout

Bahrain has offered its citizens and residents a choice of four vaccines: Pfizer/BioNTech, Sinopharm, Oxford-AstraZeneca (also known as Covisheild), and Sputnik V. Johnson & Johnson's vaccine has also been approved for emergency use. The Pfizer vaccine was the second in the world to be granted emergency-use authorization by Bahrain, and the country has also approved a Chinese vaccine made by Sinopharm. The AstraZeneca-Oxford vaccine is manufactured in India, and the Sputnik V vaccine utilises the same viral vector method.

Bahrain offers four vaccines to citizens and residents for free

Bahrain has been offering its citizens and residents a choice of four vaccines for free since December 2020. The vaccines available are the Pfizer/BioNTech vaccine, the Sinopharm vaccine from China, the Oxford-AstraZeneca vaccine (also known as Covisheild), and Russia's Sputnik V vaccine. Johnson & Johnson's vaccine has also been approved for emergency use.

The Pfizer vaccine is based on mRNA technology, which includes a genetic code that informs human cells to create the COVID-19 spike protein. This protein is then released and attacked by the immune system. During trials, Pfizer reported the highest rate of efficacy at 97%. The Sinopharm vaccine is a more traditional vaccine that uses dead particles of the virus to expose the immune system to it without risking a reaction. It reported a 79% efficacy rate during trials. The AstraZeneca-Oxford vaccine is a collaboration between the British-Swedish pharmaceutical company and the research team at Oxford University, and it is manufactured in India. This vaccine is made using a viral vector method that utilizes a common cold virus called adenovirus, which has been modified to carry the COVID-19 virus. This method weakens the vaccine but still allows for the creation of antibodies. Its efficacy is estimated at around 70%. The Sputnik V vaccine also utilizes the same viral vector method as the AstraZeneca vaccine.

Bahrain's decision to offer these vaccines for free is part of its national COVID-19 response, which strongly prioritizes protecting the health of its citizens and residents. The distribution of the vaccines is done through 27 medical centers, with the aim of providing 10,000 doses daily.

The Pfizer vaccine is from the US and uses mRNA technology

Bahrain has been offering its citizens and residents a choice of four vaccines, one of which is the Pfizer vaccine. This vaccine is from the US and uses mRNA technology.

The Pfizer vaccine was the second in the world to be granted emergency-use authorization by Bahrain, following the UK, which was the first. The vaccine contains a piece of genetic code that trains the immune system to recognize the spike protein on the surface of the virus. This genetic code informs human cells to create the COVID-19 spike protein, which will then be released and attacked by our immune system.

Pfizer reported the highest rate of efficacy during trials, with a 97% success rate. The vaccine, however, must be stored and shipped at ultra-cold temperatures of around minus 70 degrees Celsius (or 94 degrees Fahrenheit). This posed a challenge for Bahrain, a country that regularly sees temperatures of around 40 degrees Celsius (104 Fahrenheit) with high humidity.

The Pfizer vaccine is one of the four vaccines offered free of charge to citizens and residents of Bahrain. The other vaccines offered are the Oxford-AstraZeneca vaccine, the Sputnik V vaccine, and the Sinopharm vaccine.

The AstraZeneca-Oxford vaccine is a collaboration between the British-Swedish pharma company and Oxford University

Bahrain has been offering its citizens and residents a choice of four vaccines: Pfizer/BioNTech, Sinopharm, Oxford-AstraZeneca, and Sputnik V. Johnson & Johnson's vaccine has also been approved for emergency use. The AstraZeneca-Oxford vaccine, also known as Covisheild, is a collaboration between the British-Swedish pharmaceutical company and the research team at Oxford University. However, the vaccine itself is manufactured in India.

The AstraZeneca-Oxford vaccine is made using a "Viral Vector" method. This approach utilizes a common cold virus called adenovirus and mounts a modified version of COVID-19 onto it. This process significantly weakens the vaccine, but it is still potent enough to trigger the creation of antibodies. The efficacy of this vaccine is estimated to be around 70%.

The "Viral Vector" technology employed in the AstraZeneca-Oxford vaccine is a strategic approach to vaccine development. By using a weakened version of a different virus (in this case, a common cold virus), the vaccine stimulates an immune response without causing the disease. This method has been successfully used in other vaccines and provides a platform for creating safe and effective vaccines.

The collaboration between AstraZeneca and Oxford University showcases the importance of public-private partnerships in addressing global health challenges. By combining the expertise of a leading pharmaceutical company with the innovative research capabilities of a top university, the partnership has contributed to the global effort to combat the COVID-19 pandemic.

The development and distribution of the AstraZeneca-Oxford vaccine have played a crucial role in the fight against COVID-19, particularly in Bahrain's efforts to protect its population. By offering this vaccine as one of the options, along with others, Bahrain has been able to accelerate its vaccination drive and work towards the goal of getting more than 50% of its population fully vaccinated.

The Sinopharm vaccine is a traditional vaccine from China

Bahrain has been offering its citizens and residents a choice of four vaccines: Pfizer/BioNTech, Sinopharm, Oxford-AstraZeneca (also known as Covisheild), and Sputnik V. Johnson & Johnson's vaccine has also been approved for emergency use. Of these, the Sinopharm vaccine is a traditional vaccine from China.

The Sinopharm vaccine is an "inactivated" vaccine, which means it is made by growing the whole virus in a lab and then killing it. This process exposes the immune system to the dead particles of the virus without risking a reaction. In comparison, the Pfizer vaccine is an mRNA vaccine that utilizes new technology and includes genetic code. The AstraZeneca vaccine is made using a "Viral Vector" method, which mounts a modified version of COVID-19 onto a common cold virus called adenovirus. The Sputnik V vaccine also utilizes the same "Viral Vector" method as the AstraZeneca vaccine.

The Sinopharm vaccine was the first to be approved for use in Bahrain and is provided free of charge to citizens and residents. Bahrain has also turned an underused shopping mall into a vaccination hub, offering the Pfizer and Sinopharm shots. This has helped speed up the country's progress towards getting more than 50% of its population fully vaccinated.

In addition to its vaccination efforts, Bahrain has implemented other measures to protect its population from COVID-19. For example, the government has moved 8,000 laborers to new accommodations, disinfected housing, and implemented a rule requiring no more than five laborers per room, with about 3 meters (10 feet) of space for each person. Bahrain has also invested in developing vaccine manufacturing facilities to cater to the larger region and has licensed facilities for producing food supplements and facemasks.

Sputnik V is a Russian vaccine that uses the same method as the AstraZeneca vaccine

Bahrain offers its citizens and residents four vaccines free of charge: the Pfizer/BioNTech vaccine, the Oxford-AstraZeneca vaccine, the Sputnik V vaccine, and one manufactured by China's Sinopharm. Johnson & Johnson's vaccine has also been approved for emergency use.

A study by Oxford University, called Com-COV, found that mixing doses of the AstraZeneca and Pfizer vaccines produced high levels of antibodies against the coronavirus spike protein. The highest antibody response was seen in people receiving two doses of the Pfizer vaccine, with both mixed schedules producing better responses than two doses of the AstraZeneca vaccine. An AstraZeneca shot followed by Pfizer produced the best T-cell responses and a higher antibody response than Pfizer followed by AstraZeneca.

Frequently asked questions